NRX Pharmaceuticals

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NRx Pharmaceuticals reports strong Q1 performance and growth opportunities

NRx Pharmaceuticals made strides in innovation, debt reduction, and financial stability in Q1 2024.
The company's focus on mental health treatments and addressing unmet medical needs shows market relevance.
Challenges include resolving short interest concerns and securing FDA approvals for key drugs.
Opportunities lie in out-licensing, revenue generation, and partnerships for growth and market expansion.

NRx Pharmaceuticals reports progress in financials and scientific breakthroughs

NRx Pharmaceuticals showcased financial and scientific progress, positioning itself for growth and market penetration.
Strategic initiatives like clinic roll-up and commercial targeting demonstrate a proactive approach to market challenges.
While facing transitions and competition, NRx Pharmaceuticals has opportunities for expansion and innovation in psychiatric treatments.
The company's focus on financial stability, product development, and market strategies reflects a comprehensive growth strategy.

NRx Pharmaceuticals reports improved financials and plans for growth

NRx Pharmaceuticals demonstrated improved financial performance and strategic planning in Q3 2024, with reduced losses and enhanced operational efficiency.
The company's focus on innovation, acquisitions, and precision psychiatry clinics highlights a commitment to growth and market leadership.
While facing challenges in revenue recognition and clinic valuations, NRx Pharmaceuticals has opportunities to drive revenue growth and expand its market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NRx Pharmaceuticals NRXP has announced the private placement of 7.8 million shares priced at a premium to market under Nasdaq rule, for gross proceeds of $25 million. [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.

NRx Pharmaceuticals Raises $25M Via Equity To Support Its Pipeline Development

RADNOR, Pa., Jan. 31, 2022 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) (or the "Company"), a Delaware corporation, today announced that it has entered into definitive agreements with investors to purchase 7,824,727 shares of common stock in a private placement priced at a premium to market under Nasdaq rules.

NRx Pharmaceuticals Announces $25 Million Private Placement Priced at a Premium to Market under Nasdaq Rules

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 21, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired NRx Pharmaceuticals, Inc. (“NRx” or the “Company”) (NASDAQ: NRXP) securities between June 1, 2021 and November 4, 2021, inclusive (the “Class Period”). If you suffered a loss on your NRx investments or would like to inquire about potentially pursuing cla

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NRx Pharmaceuticals, Inc. (NRXP)

The Company also said that many of the mutations in the omicron variant had been identified in the spike protein of the BriLife vaccine.

NRx Pharma's COVID-19 Vaccine Candidate Show Potential Against Omicron Variant

RADNOR, Pa., Jan. 27, 2022 /PRNewswire/ -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company has received scientific evidence from the Israel Institute for Biological Research (IIBR) that the BriLife® vaccine may produce effective levels of neutralizing antibody against the Omicron variant of the SARS-CoV-2 virus.1 More importantly, many of the mutations (alterations) that cause the Omicron variant spike protein to differ from the spike protein of the original SARS-CoV-2 virus that causes COVID-19 have been identified in the spike protein of the BriLife vaccine.

NRx Announces Publication of Initial Findings of BriLife® Vaccine-produced Antibodies Against Omicron Variant

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming March 21, 2022 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased NRx Pharmaceuticals, Inc. (“NRx” or the “Company”) (NASDAQ: NRXP) securities between June 1, 2021 and November 4, 2021, inclusive (the “Class Period”). Investors suffering losses on their NRx investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rig

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NRx Pharmaceuticals, Inc. (NRXP)

RADNOR, Pa., Jan. 26, 2022 /PRNewswire/ -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, has received a first safety report from a Southwestern hospital where physicians have administered ZYESAMI® (Aviptadil) to patients with COVID-19 respiratory failure.

NRx Receives Initial Report of Patient Safety and Survival from Right to Try use of ZYESAMI® (aviptadil) during Omicron Surge

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired NRx Pharmaceuticals, Inc. (“NRx” or the “Company”) (NASDAQ: NRXP) securities between June 1, 2021 and November 4, 2021, inclusive (the “Class Period”). NRx investors have until March 21, 2022 to file a lead plaintiff motion. If you suffered a loss on your NRx investme

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of NRx Pharmaceuticals, Inc. (NRXP) Investors

SAN DIEGO--(BUSINESS WIRE)---- $NRXP #COVID19--NRx Pharmaceutical, Inc. (NRXP) Misled Investors Regarding the EAU Status of its Drug Candidate

Shareholder Alert: Robbins LLP Reminds Investors that NRx Pharmaceuticals, Inc. (NRXP) is Being Sued for Misleading Shareholders

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased NRx Pharmaceuticals, Inc. (“NRx” or the “Company”) (NASDAQ: NRXP) securities between June 1, 2021 and November 4, 2021, inclusive (the “Class Period”). NRx investors have until March 21, 2022 to file a lead plaintiff motion. Investors suffering losses on their NRx investments are encouraged to contact the Law Offices of Howard G. Smith to discu

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of NRx Pharmaceuticals, Inc. (NRXP) Investors

San Diego, California--(Newsfile Corp. - January 20, 2022) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) (NASDAQ: NRXPW) securities between June 1, 2021 and November 4, 2021, inclusive (the "Class Period") have until March 21, 2022 to seek appointment as lead plaintiff in Dal Bosco v. NRx Pharmaceuticals, Inc., No. 22-cv-00066 (D. Del.). Commenced on January 18, 2022, the NRx Pharma class...

DEADLINE: NRx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NRXP; NRXPW

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of NRx Pharmaceuticals, Inc. (“NRx” or the “Company”) (NASDAQ: NRXP) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your NRx investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities law

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of NRx Pharmaceuticals, Inc. (NRXP) on Behalf of Investors

Shareholder Alert: Robbins LLP Informs Investors that NRx Pharmaceuticals, Inc. (NRXP) is Being Sued for Misleading Shareholders

LOS ANGELES--(BUSINESS WIRE)---- $NRXP #NRXP--The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $NRXP #investors--The Law Offices of Frank R. Cruz Announces Investigation of NRx Pharmaceuticals, Inc. (NRXP) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of NRx Pharmaceuticals, Inc. (NRXP) on Behalf of Investors

SAN DIEGO--(BUSINESS WIRE)-- #NRXPWstock--The suit alleges defendants issued false statements concerning NRx business and prospects, resulting in its stock trading at inflated prices.

ALERT: NRx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NRXP; NRXPW

NEW YORK--(BUSINESS WIRE)-- #Class--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against NRx Pharmaceuticals, Inc. (“NRx” or the “Company”) (NASDAQ: NRXP, NRXPW) in the United States District Court for the District of Delaware on behalf of all persons and entities who purchased or otherwise acquired NRx securities between June 1, 2021 and November 4, 2021, both dates inclusive (the “Class Period”). Inve

NRX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against NRx Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of NRx Pharmaceuticals, Inc. (“NRx” or the “Company”) (NASDAQ: NRXP) investors concerning the Company's possible violations of the federal securities laws. In June 2021, NRx announced that it filed an application with U.S. Food and Drug Administration (“FDA”) requesting Emergency Use Authorization (“EUA”) for ZYESAMI (Aviptadil-acetate) to treat critically ill COVID-19 patients suffering with res

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of NRx Pharmaceuticals, Inc. (NRXP) on Behalf of Investors

New York, New York--(Newsfile Corp. - January 19, 2022) - Gainey McKenna & Egleston announces that a class action lawsuit has been filed against NRx Pharmaceuticals, Inc. ("NRx") (NASDAQ: NRXP) (NASDAQ: NRXPW) in the United States District Court for the District of Delaware on behalf of investors who purchased NRx's common stock between June 1, 2021 and November 4, 2021, both dates inclusive (the "Class Period").The Complaint alleges that Defendants made false and/or misleading statements...

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against NRx Pharmaceuticals, Inc. (NRXP; NRXPW)

FIGS

OptimizeRx Corp

Here's why our roundtable participants like NRx Pharmaceuticals, FIGS, and OptimizeRx.

3 Under-the-Radar COVID Stocks

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP; NRXPW) between June 1, 2021 and November 4, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 21, 2022. SO WHAT: If you purchased NRx securities during the Class Pe

NRXP EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages NRx Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – NRXP; NRXPW

NRx Pharmaceuticals (NASDAQ: NRXP) has announced enhancements to its Expanded Access and Right to Try programs.  The programs enable patients to receive Zyesami (aviptadil) upon a physician's prescription, with respiratory failure from COVID-19, who have tried all approved medicines, including remdesivir, and who cannot participate in a clinical study.

NRx Pharma's Zyesami Access Expanded To COVID-19 Patients Who Exhausted All Approved Treatments

RADNOR, Pa., Jan. 18, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP) today announced enhancements to its Expanded Access and Right to Try programs. The programs enable patients with respiratory failure from COVID-19, who have tried all approved medicines, including remdesivir, and who are not able to participate in a clinical study, to receive ZYESAMI® (aviptadil) upon a physician's prescription.

NRx Pharmaceuticals Announces Expansion of ZYESAMI® (aviptadil) US Expanded Access and Right to Try Programs for Patients with COVID-19 Respiratory Failure who have Exhausted All Approved Treatments

RADNOR, Pa., Jan. 14, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, responded to today's press release issued by Relief Therapeutics.

NRx Responds to Relief's Allegations of January 14, 2022

NRx Pharmaceuticals Inc (NASDAQ: NRXP) has filed a counterclaim against its former partner, Relief Therapeutics Holdings (OTC: RLFTF), in an ongoing dispute over the COVID-19 treatment Zyesami (avaptadil). NRx alleges that Relief has breached a collaboration agreement and falsely asserted worldwide right to Zyesami.

News for NRX Pharmaceuticals Stock (NRXP)